| アブストラクト | Prescription of vesicular monoamine transporter 2 (VMAT2) inhibitors, valbenazine, deutetrabenazine, and tetrabenazine, is becoming increasingly common in persons treated with antipsychotics. Reported suicidality and parkinsonism are safety concerns with VMAT2 inhibitors. Herein, we aim to evaluate the aforementioned safety outcomes using the FDA Adverse Event Reporting System. Reporting odds ratios (RORs) and lower limits of 95% confidence intervals of information components (IC025) were calculated to quantify VMAT2 inhibitor-associated adverse events. Acetaminophen was the reference agent. Suicidal ideation was significantly associated with VMAT2 inhibitors, with RORs ranging from 2.38 to 10.67 and IC025 ranging from 0.73 to 2.39. Increased odds of suicidal behavior was observed with tetrabenazine (ROR 3.011, IC025 0.0087), but not deutetrabenazine or valbenazine. Decreased odds of suicide attempts and completed suicide were observed with VMAT2 inhibitors, with RORs ranging from 0.011 to 0.10 (all IC025 < 0). Increased odds of parkinsonism were reported for all VMAT2 inhibitors, with RORs and IC025 ranging from 19.49 to 25.37 and 1.66 to 2.93, respectively. The mixed results with VMAT2 inhibitor-associated suicidality and parkinsonism do not establish causal relationships. The parameters of suicidality may be explained by underlying psychiatric disorders. |
|---|
| ジャーナル名 | International clinical psychopharmacology |
|---|
| 投稿日 | 2024/5/10 |
|---|
| 投稿者 | Wong, Sabrina; Le, Gia Han; Kwan, Angela T H; Rhee, Taeho Greg; Teopiz, Kayla M; Ho, Roger C; Cao, Bing; Rosenblat, Joshua D; Mansur, Rodrigo; McIntyre, Roger S |
|---|
| 組織名 | Brain and Cognition Discovery Foundation.;Department of Pharmacology and Toxicology, University of Toronto.;Clinical Research Unit, Mood Disorder Psychopharmacology Unit, University Health;Network.;Institute of Medical Science, University of Toronto, Toronto.;Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.;Department of Psychiatry, Yale School of Medicine, New Haven.;Department of Public Health Sciences, University of Connecticut School of;Medicine, Farmington, Connecticut, USA.;Department of Psychological Medicine, Yong Loo Lin School of Medicine.;Institute for Health Innovation and Technology (iHealthtech), National University;of Singapore, Singapore.;Division of Life Science (LIFS), Hong Kong University of Science and Technology;(HKUST), Clear Water Bay, Hong Kong.;School of Psychology and Key Laboratory of Cognition and Personality (Ministry of;Education), Southwest University, Chongqing, P.R. China and.;Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38727416/ |
|---|
